Nathan den Broeder

15PUBLICATIONS
25CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Soil chemistry and soil carbon sequestration (excl. carbon sequestration science)Regenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Aug 18, 2026
Subcutaneous versus intravenous ultra-low dose rituximab in rheumatoid arthritis: a randomised controlled PK-PD non-inferiority trial.

|Aug 25, 2025
Long-Term Routine Laboratory Toxicity Monitoring of Immunomodulatory Drugs in Rheumatoid Arthritis : A Retrospective Cohort Study.

Evy Ulijn, Nathan den Broeder, Karen Bevers

|Aug 12, 2025
Continuation Versus Temporary Interruption of Immunomodulatory Agents During Infections in Patients With Inflammatory Rheumatic Diseases: A Randomized Controlled Trial.

Merel A A Opdam, Nathan den Broeder, Reinout van Crevel

|Jun 25, 2025
Cycle versus swap strategy after TNFi discontinuation in psoriatic arthritis and axial spondyloarthritis: a quasi-experimental study.

Ilse van Es, Johanna E Vriezekolk, Nathan den Broeder

|Jun 13, 2024
Effect of using the Simple Erosion Narrowing Score or Sharp/van der Heijde score on the power of rheumatoid arthritis clinical trials to detect differences in radiographic progression.

Nathan den Broeder, Thomas E Bolhuis, Noortje van Herwaarden

|Apr 10, 2024
Long-term clinical and radiological effectiveness and safety of ultralow doses of rituximab in rheumatoid arthritis: observational extension of the REDO trial.

Nathan den Broeder, Lise Verhoef, Yaël A de Man

Pageof 3

Frequent Collaborators

4 joint publications

Alfons A den Broeder

2 joint publications

Celia Aj Michielsens

2 joint publications

Thomas E Bolhuis

2 joint publications

Noortje van Herwaarden